Myelofibrosis-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 89-101

  Mughal, Tariq I ^a   Vaddi, Kris ^b   Sarlis, Nicholas J ^b   Verstovsek, Srdan ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Experimental Station   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Extramedullary hematopoiesis; JAK inhibitor; Myelofibrosis; Myeloproliferative neoplasm; Ruxolitinib

Indexed keywords

EID: 84893271034     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/ijgm.s51800     Document Type: Article

References (108)

1. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
2. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011;9(9 Suppl 22):1-16.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13): 2895-2901.
4. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15): 2857-2858.
5. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. Epub July 29, 2013.
6. Aksoy M. Malignancies due to occupational exposure to benzene. Haematologica. 1980;65(3):370-373.
7. Tondel M, Persson B, Carstensen J. Myelofibrosis and benzene exposure. Occup Med (Lond). 1995;45(1):51-52.
8. Bosch X, Campistol JM, Montoliu J, Revert L. Myelofibrosis and focal segmental glomerulosclerosis associated with toluene poisoning. Hum Toxicol. 1988;7(4):357-361.
9. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale R P. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011;35(1): 12-13.
10. Jakaf® (Ruxolitinib) tablets, for oral use [prescribing information]. Wilmington, DE: Incyte Corporation. Available from: http://www.incyte.com/products/uspi_jakaf.pdf. Accessed September 9, 2013.
11. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
12. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with rux-olitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
13. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
14. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. Epub 2013 Sept 13.
15. Cervantes F, Kiladjian JJ, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012;120(21):Abstract 801.
16. Vardiman J W, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): 937-951.
17. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al; French INSERM and the European EUMNET Networks on Myelofibrosis. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8):3026-3035.
18. Prchal JF, Axelrad AA. Bone marrow responses in polycythemia vera. N Engl J Med. 1974;290(24):1382.
19. Adamson J W, Fialkow PJ, Murphy S, Prchal J F, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295(17):913-916.
20. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58(5):916-919.
21. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005;105(4):1699-1705.
22. Röder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29(6):694-702.
23. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004;32(2):179-187.
24. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
25. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloprolif-erative disorders. Lancet. 2005;365(9464):1054-1061.
26. James C, Ugo V, Le Couédic J P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
27. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
28. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myel-oid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4): 387-397.
29. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011: 208-214.
30. Oku S, Takenaka K, Kuriyama T, et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol. 2010;150(3):334-344.
31. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-140.
32. Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2012;120(21):Abstract 1733.
33. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
34. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematologi-cal malignancies. Oncogene. 2013;32(21):2601-2613.
35. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelo-fibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26(3):475-480.
36. Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myelo-proliferative neoplasms. Haematologica. 2011;96(10):1398-1402.
37. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
38. Rumi E, Harutyunyan A, Elena C, et al. Identifcation of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011;86(12):974-979.
39. Hummel JM, Kletecka MC, Sanks JK, et al. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol. 2012;21(3): 176-183.
40. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
41. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
42. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813-2816.
43. Abdel-Wahab O, Pardanani A, Bernard OA, et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012;87(5): 562-568.
44. Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550-3560.
45. Constantinescu SN, Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? Hematology Am Soc Hematol Educ Program. 2012;2012:553-560.
46. Le Bousse-Kerdilès MC, Martyré MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw. 2008;19(2):69-80.
47. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520-8530.
48. Kreipe H, Büsche G, Bock O, Hussein K. Myelofibrosis: molecular and cell biological aspects. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S21.
49. Le Bousse-Kerdilès MC. Primary myelofibrosis and the "bad seeds in bad soil" concept. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S20.
50. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
51. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
52. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25(9):1193-1202.
53. Kröger N, Kvasnicka M, Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S25.
54. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7): 1367-1379.
55. Patriarca F, Bacigalupo A, Sperotto A, et al; GITMO. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514-1522.
56. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3): 358-367.
57. Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol. 2009;16(2): 140-146.
58. Mesa RA, Li CY, Ketterling R P, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3): 973-977.
59. Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myelo-proliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep. 2012;7(1):78-86.
60. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25-33.
61. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refned Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
62. Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26(6):1439-1441.
63. Lopes da Silva R, Ribeiro P, Lourenço A, et al. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloprolifera-tive neoplasms? Lab Hematol. 2011;17(1):12-16.
64. Helbig G, Wieczorkiewicz A, Wozńiczka K, Wisńiewska-Piaty K, Rusek A, Kyrcz-Krzemień S. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29(4):2379-2384.
65. Kreft A, Springer E, Lipka DB, Kirkpatrick CJ. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. Acta Haematol. 2009;122(1):36-38.
66. Wu YY, Hung HM, Chen TS, Chao TY, Ho CL. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation. Leuk Res. 2008;32(11):1783-1786.
67. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007; 110(1):375-379.
68. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myelopro-liferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74(1):26-31.
69. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: fnal results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29): 3907-3913.
70. Varki A, Lottenberg R, Griffth R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62(6):353-371.
71. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1): 68-76.
72. Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53(3):441-444.
73. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on defni-tion, pathogenesis, and treatment. Annu Rev Med. 2009;60:233-245.
74. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6): 761-770.
75. Michiels JJ. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond. Hematology. 2005;10 Suppl 1:215-223.
76. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990;34(4):291-300.
77. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
78. Ouellette DR. The impact of anemia in patients with respiratory failure. Chest. 2005;128(5 Suppl 2):576S-582S.
79. Prentice CR. Acquired coagulation disorders. Clin Haematol. 1985;14(2):413-442.
80. Wolach B, Gavrieli R, Manor Y, Lishner M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis. 1998;24(4): 544-551.
81. Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol. 1988;40(4):355-361.
82. O'Reilly RA. Splenomegaly at a United States County Hospital: diagnostic evaluation of 170 patients. Am J Med Sci. 1996;312(4): 160-165.
83. Alvarez-Larrán A, Abraldes JG, Cervantes F, et al. Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol. 2005;100(10):2355-2358.
84. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265.
85. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloprolif-erative diseases. Klin Wochenschr. 1989;67(16):818-825.
86. Bioulac-Sage P, Roux D, Quinton A, Lamouliatte H, Balabaud C. Ultrastructure of sinusoids in patients with agnogenic myeloid metaplasia. J Submicrosc Cytol. 1986;18(4):815-821.
87. Koch CA, Li C Y, Mesa RA, Tefferi A. Nonhepatosplenic extramedul-lary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78(10):1223-1233.
88. Nadrous HF, Krowka MJ, McClure RF, Tefferi A, Lim KG. Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformation. Leuk Lymphoma. 2004;45(4):815-818.
89. Altomare G, Capella GL, Frigerio E. Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodef-ciency complex: effcacy of treatment with etretinate. Haematologica. 1996;81(1):54-58.
90. Chan AC, Kwong YL, Lam CC. Granulocytic sarcoma of megakaryo-blastic differentiation complicating chronic idiopathic myelofibrosis. Hum Pathol. 1996;27(4):417-420.
91. Frohna BJ, Quint DJ. Granulocytic sarcoma (chloroma) causing spinal cord compression. Neuroradiology. 1993;35(7):509-511.
92. Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs. 2012;17(4):555-570.
93. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically signifcant splenomegaly. Blood. 2012;120(13): 2768-2769.
94. Santos F P, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131-1136.
95. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and effcacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
96. Pardanani A, Laborde RR, Lasho TL, et al. Safety and effcacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-1327.
97. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222-230.
98. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009;113(22):5394-5400.
99. Daver N, Shastri A, Kadia T, et al. Modest activity of pomalidomide in patients with myelofibrosis and signifcant anemia. Leuk Res. Epub July 24, 2013.
100. Celgene Corporation. Phase-3 double-blind, placebo-controlled study of pomalidomide in persons with myeloproliferative- neoplasm-associated myelofibrosis and RBC-transfusion- dependence myelofibrosis and RBC-transfusion-dependence (RESUME). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 13, 2012]. Available from: http://clinicaltrials.gov/show/NCT01178281. NLM identifier: NCT01178281. Accessed September 9, 2013.
101. Celgene Corporation. Celgene reports first quarter 2013 operating and financial results [web page on the Internet]. Summit, NJ: Cel-gene Corporation; nd. Available from: http://ir.celgene.com/phoenix.zhtml?c=111960&ol-newsArticle&ID=1811033&highlight=myelofibrosis. Accessed August 19, 2013.
102. JAKAVI® the first medication to receive health Canada approval to treat patients with myelofibrosis [press release]. CNW Group; 2012 [July 5]. Available from: http://www.newswire.ca/en/story/1003655/-pr-jakavi-the-frst-medication-to-receive-health-canada-approval-to-treat-patients-with-myelofibrosis. Accessed July 17, 2013.
103. Novartis AG. Novartis drug JAKAVI® frst medication to receive European Commission approval to treat patients with myelofibrosis [media release]. Basel: Novartis AG; 2012 [Aug 28]. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtml. Accessed July 17, 2013.
104. Incyte Corporation. COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial. In: ClinicalTri-als.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated May 13, 2013]. Available from: http://clinicaltrials.gov/show/NCT00952289. NLM identifer: NCT00952289. Accessed September 9, 2013.
105. Novartis Pharmaceuticals. COntrolled MyeloFibrosis study with ORal Janus-associated kinase (JAK) inhibitor Treatment-II: The COMFORT-II Trial. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated March 12, 2013]. Available from: http://clinicaltrials.gov/show/NCT00934544. NLM identifier: NCT00934544. Accessed September 9, 2013.
106. Incyte Corporation. Open label ruxolitinib (INCB018424) in patients with myelofibrosis and post polycythemia vera/essential throm-bocythemia myelofibrosis. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2007 [updated October 9, 2012]. Available from: http://clinicaltrials.gov/show/NCT00509899. NLM identifier: NCT00509899. Accessed September 9, 2013.
107. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol. 2013;31(Suppl):Abstract 7030.
108. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother. 2012;13(16):2397-2407.